SG11201805913QA - New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents
New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- SG11201805913QA SG11201805913QA SG11201805913QA SG11201805913QA SG11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- utca
- berkshire
- budapest
- pct
- Prior art date
Links
- 150000003863 ammonium salts Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241001581492 Attila Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1650411A FR3046792B1 (fr) | 2016-01-19 | 2016-01-19 | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/EP2016/081688 WO2017125224A1 (en) | 2016-01-19 | 2016-12-19 | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805913QA true SG11201805913QA (en) | 2018-08-30 |
Family
ID=55752504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805913QA SG11201805913QA (en) | 2016-01-19 | 2016-12-19 | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them |
Country Status (43)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
| KR102576567B1 (ko) * | 2017-01-06 | 2023-09-07 | 르 라보레또레 쎄르비에르 | Mcl-1 억제제와 탁산 화합물의 조합물, 이의 용도 및 약학적 조성물 |
| CN111032050B (zh) | 2017-06-22 | 2024-01-19 | 法国施维雅药厂 | Mcl-1抑制剂与用于血液癌症的标准治疗的组合，其用途和药物组合物 |
| CA3073108A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| JP2020531457A (ja) * | 2017-08-15 | 2020-11-05 | アッヴィ・インコーポレイテッド | 大環状ｍｃｌ−１阻害剤及び使用の方法 |
| US10676485B2 (en) | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| CN108424417B (zh) * | 2017-12-21 | 2019-09-20 | 河南真实生物科技有限公司 | 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用 |
| AR116635A1 (es) | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
| TW202038960A (zh) | 2018-11-14 | 2020-11-01 | 法商施維雅藥廠 | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 |
| MX2021006702A (es) * | 2018-12-06 | 2021-07-07 | Servier Lab | Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen. |
| US20230081720A1 (en) | 2019-05-20 | 2023-03-16 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| AR119156A1 (es) | 2019-06-17 | 2021-11-24 | Servier Lab | Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma |
| WO2021067827A1 (en) * | 2019-10-03 | 2021-04-08 | California Institute Of Technology | Mcl1 inhibitors and uses thereof |
| CN117136076A (zh) | 2020-11-24 | 2023-11-28 | 诺华股份有限公司 | Mcl-1抑制剂抗体药物缀合物和使用方法 |
| WO2022216946A1 (en) * | 2021-04-07 | 2022-10-13 | California Institute Of Technology | Mcl1 inhibitors and uses thereof |
| JP2024521947A (ja) | 2021-06-11 | 2024-06-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TW202315637A (zh) | 2021-06-11 | 2023-04-16 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650425A (en) * | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
| EP0981337A4 (en) * | 1997-02-09 | 2003-03-12 | Pharmos Corp | IMPROVED ANTI-ANGIOGENIC ACTIVITY OF CONSTANTLY LOADED DERIVATIVES OF STEROID HORMONES |
| JP2008505084A (ja) * | 2004-06-29 | 2008-02-21 | アムゲン インコーポレイティッド | フラノピリミジン |
| US8129371B2 (en) * | 2007-10-16 | 2012-03-06 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors |
| EP2276346B1 (en) * | 2008-04-30 | 2016-11-23 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
| KR101703941B1 (ko) * | 2008-11-10 | 2017-02-07 | 내셔날 헬스 리서치 인스티튜트 | 티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물 |
| CN102464667B (zh) * | 2010-11-03 | 2014-06-04 | 中国科学院上海药物研究所 | 一类五元杂环并嘧啶类化合物及其制备方法和用途 |
| EP2920169A1 (en) * | 2012-11-14 | 2015-09-23 | F. Hoffmann-La Roche AG | Imidazopyridine derivatives |
| AU2014261585B2 (en) * | 2013-05-02 | 2018-03-08 | F. Hoffmann-La Roche Ag | Purine derivatives as CB2 receptor agonists |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2016
- 2016-01-19 FR FR1650411A patent/FR3046792B1/fr not_active Expired - Fee Related
- 2016-12-19 DK DK16816667.6T patent/DK3405471T3/da active
- 2016-12-19 SI SI201630558T patent/SI3405471T1/sl unknown
- 2016-12-19 MY MYPI2018702472A patent/MY196352A/en unknown
- 2016-12-19 CN CN201680080679.7A patent/CN108602841B/zh active Active
- 2016-12-19 PE PE2018001293A patent/PE20190336A1/es unknown
- 2016-12-19 PL PL16816667T patent/PL3405471T3/pl unknown
- 2016-12-19 AU AU2016387870A patent/AU2016387870B2/en active Active
- 2016-12-19 WO PCT/EP2016/081688 patent/WO2017125224A1/en active Application Filing
- 2016-12-19 JP JP2018555822A patent/JP6871275B2/ja active Active
- 2016-12-19 US US16/069,891 patent/US10457689B2/en active Active
- 2016-12-19 MX MX2018008808A patent/MX2018008808A/es active IP Right Grant
- 2016-12-19 EP EP16816667.6A patent/EP3405471B1/en active Active
- 2016-12-19 EA EA201891622A patent/EA036932B1/ru unknown
- 2016-12-19 TN TNP/2018/000239A patent/TN2018000239A1/en unknown
- 2016-12-19 RU RU2018129308A patent/RU2743098C2/ru active
- 2016-12-19 CR CR20180363A patent/CR20180363A/es unknown
- 2016-12-19 CA CA3011761A patent/CA3011761C/en active Active
- 2016-12-19 PT PT168166676T patent/PT3405471T/pt unknown
- 2016-12-19 HU HUE16816667A patent/HUE048449T2/hu unknown
- 2016-12-19 ME MEP-2019-336A patent/ME03555B/me unknown
- 2016-12-19 MD MDE20181134T patent/MD3405471T2/ro unknown
- 2016-12-19 GE GEAP201614858A patent/GEP20207126B/en unknown
- 2016-12-19 KR KR1020187023819A patent/KR20180098677A/ko not_active Application Discontinuation
- 2016-12-19 MA MA43639A patent/MA43639B1/fr unknown
- 2016-12-19 BR BR112018014536-0A patent/BR112018014536B1/pt active IP Right Grant
- 2016-12-19 UA UAA201808693A patent/UA123508C2/uk unknown
- 2016-12-19 LT LT16816667T patent/LT3405471T/lt unknown
- 2016-12-19 CU CU2018000073A patent/CU20180073A7/es unknown
- 2016-12-19 ES ES16816667T patent/ES2760545T3/es active Active
- 2016-12-19 RS RS20191499A patent/RS59622B1/sr unknown
- 2016-12-19 SG SG11201805913QA patent/SG11201805913QA/en unknown
-
2018
- 2018-07-10 SV SV2018005722A patent/SV2018005722A/es unknown
- 2018-07-11 IL IL260550A patent/IL260550B/en active IP Right Grant
- 2018-07-12 PH PH12018501506A patent/PH12018501506A1/en unknown
- 2018-07-13 CL CL2018001908A patent/CL2018001908A1/es unknown
- 2018-07-16 CO CONC2018/0007443A patent/CO2018007443A2/es unknown
- 2018-07-17 NI NI201800076A patent/NI201800076A/es unknown
- 2018-07-17 ZA ZA2018/04770A patent/ZA201804770B/en unknown
- 2018-07-17 EC ECSENADI201853634A patent/ECSP18053634A/es unknown
- 2018-07-19 SA SA518392049A patent/SA518392049B1/ar unknown
-
2019
- 2019-11-19 HR HRP20192073TT patent/HRP20192073T1/hr unknown
-
2020
- 2020-01-27 CY CY20201100072T patent/CY1122560T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805913QA (en) | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201810576QA (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201810629QA (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer |